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Onasemnogene abeparvovec for presymptomatic
infants with two copies of SMN2 at risk for spinal
muscular atrophy type 1: the Phase III SPR1NT trial
Kevin A. Strauss 1,2,3 ✉, Michelle A. Farrar 4,5, Francesco Muntoni6,7, Kayoko Saito 8,
Jerry R. Mendell9,10, Laurent Servais 11,12, Hugh J. McMillan 13, Richard S. Finkel 14,15,
Kathryn J. Swoboda 16, Jennifer M. Kwon17, Craig M. Zaidman18, Claudia A. Chiriboga19,
Susan T. Iannaccone 20, Jena M. Krueger21, Julie A. Parsons22, Perry B. Shieh23, Sarah Kavanagh24,
Sitra Tauscher-Wisniewski24, Bryan E. McGill 25 and Thomas A. Macek 24
SPR1NT (NCT03505099) was a Phase III, multicenter, single-arm study to investigate the efficacy and safety of onasemnogene
abeparvovec for presymptomatic children with biallelic SMN1 mutations treated at ≤6 weeks of life. Here, we report final results
for 14 children with two copies of SMN2, expected to develop spinal muscular atrophy (SMA) type 1. Efficacy was compared
with a matched Pediatric Neuromuscular Clinical Research natural-history cohort (n = 23). All 14 enrolled infants sat independently for ≥30 seconds at any visit ≤18 months (Bayley-III item #26; P < 0.001; 11 within the normal developmental window).
All survived without permanent ventilation at 14 months as per protocol; 13 maintained body weight (≥3rd WHO percentile)
through 18 months. No child used nutritional or respiratory support. No serious adverse events were considered related to
treatment by the investigator. Onasemnogene abeparvovec was effective and well-tolerated for children expected to develop
SMA type 1, highlighting the urgency for universal newborn screening.

S

pinal muscular atrophy (SMA) results from biallelic deletions or mutations of SMN1, which encodes the survival
motor neuron (SMN) protein essential for the development
and viability of motor neurons in the ventral spinal cord1. SMN2,
a gene homologous to SMN1, produces minimal SMN protein and
exists in multiple copies in humans2. SMN2 copy number correlates with the onset and severity of SMA3. Two copies are 79%
predictive of severe, infantile-onset SMA type 1, three copies are
54% predictive of intermediate severity SMA type 2, and four copies are 88% predictive of a milder SMA type 3 phenotype with
later onset3.
The classic clinical presentation of untreated SMA type 1 is characterized by onset of flaccid weakness and motor regression within
the first 6 months of life, followed by progressive muscle wasting, dysphagia, respiratory failure, and untimely death4–7. Two prospective

observational studies (Pediatric Neuromuscular Clinical Research
[PNCR] and NeuroNEXT)7,8 charted the natural course of SMA
type 1 and delineated meaningful trial endpoints, including survival. Untreated children do not achieve or maintain a Children’s
Hospital of Philadelphia Infant Test of Neuromuscular Disorders
(CHOP INTEND; range of 0–64, with lower scores indicating
reduced motor function) score of ≥40 after age 6 months, and none
achieve independent sitting or more advanced motor milestones.
Median ventilator-free survival of patients with SMA type 1 (two
SMN2 copies) is between 8 months (NeuroNEXT) and 10.5 months
(PNCR); most children who survive to 18 months require non-oral
feeding support, and 100% die or require permanent ventilation
by 2 years of age. Untreated patients with SMA type 2 sit independently but do not walk, whereas untreated patients with SMA type 3
develop independent walking.
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There are now three approved therapies for SMA. Two augment production of intact SMN protein from each SMN2 copy9
but require repeated intrathecal (nusinersen) or oral (risdiplam)
dosing. Onasemnogene abeparvovec is a genetically engineered
adeno-associated virus type 9 (AAV9) vector designed to express
SMN protein in tissues following one-time intravenous infusion10.
Intravenous onasemnogene abeparvovec traverses the blood–brain
barrier to transfect neurons and glia throughout the nervous system,
and also transfects muscle, liver, and other peripheral tissues11,12.
Onasemnogene abeparvovec is a recombinant self-complementary
AAV9 containing a human SMN transgene under the control of a
chicken β-actin promoter and cytomegalovirus enhancer, which
together ensure rapid and sustained transcription of SMN messenger RNA.
In two Phase III clinical trials of one-time intravenous
onasemnogene abeparvovec infusion, patients with symptomatic
SMA type 1 who were younger than 6 months of age were treated
with 1.1 × 1014 vector genomes (vg)/kg (STR1VE-US, n = 22;
STR1VE-EU, n = 33)13,14. Both studies provide evidence that SMN
gene replacement via intravenous onasemnogene abeparvovec
improves survival and motor development for patients with SMA
type 1. At age 14 months, 91% (STR1VE-US) and 97% (STR1VE-EU)
of treated patients were alive and free from permanent ventilation,
as compared with 26% in the historical PNCR cohort. Rapid and
sustained improvements in motor function were observed in both
trials: (1) CHOP INTEND scores reached or exceeded 40 for 21
(95%) patients in STR1VE-US and 24 (73%) in STR1VE-EU; (2)
many patients sat independently by 18 months of age (14 of 22
(64%) for ≥30 seconds (Bayley #26) in STR1VE-US and 14 of 32
(44%) for ≥10 seconds (World Health Organization; WHO) in
STR1VE-EU); and (3) one patient from each study walked independently for at least five steps by 18 months of age (5%, STR1VE-US
and 3%, STR1VE-EU [Bayley #43]). Similar motor milestone gains
have been replicated in patients treated with intravenous onasemnogene abeparvovec in real-world settings15 (unpublished data,
Servais, L., Day, J.W., De Vivo, D.C., Mercuri, E. & Muntoni, F).
A recent analysis summarized onasemnogene abeparvovec safety
data from seven clinical trials (n = 102) as well as post-marketing
reports (n = 665) through 12 November 202016. In clinical trials,
liver transaminases increased transiently in 90 of 102 (90%) patients
and, in some cases, exceeded three times the upper limit of normal
(ULN) (9% mild ≥3× ULN to <5× ULN; 6% ≥5× to <20× ULN;
and 5% ≥20× ULN)17. Hepatotoxicity events resolved over time with
prednisolone treatment. Transient decreases in platelets (<75,000
cells/µL) were also observed after vector administration16. In the
post-marketing setting, transient hepatotoxicity, including four cases
of acute liver failure, was the most common adverse event (AE). In
addition, thrombotic microangiopathy (TMA) was observed in the
post-marketing setting16. Although not observed clinically, cardiac
thrombi and dorsal root ganglia toxicities were observed in nonclinical toxicology studies16. From these data, the study sponsor (Novartis
Gene Therapies) identified five categories of potential AEs of special interest (AESIs), which include hepatotoxicity, thrombocytopenia, cardiac events, TMA, and sensory abnormalities suggestive of
ganglionopathy. Overall, onasemnogene abeparvovec has demonstrated a favorable benefit–risk profile for patients with SMA who
are younger than 2 years of age13,14,18–20. However, data covering its
administration during the presymptomatic neonatal period have not
been systematically collected or reported until now.
The objective of SPR1NT was to evaluate the efficacy and safety
of onasemnogene abeparvovec for children with genetically confirmed SMA prior to clinical disease onset, based on the hypothesis
that earlier administration of SMN gene therapy results in better
outcomes21. Data from Phase I START18,19 and Phase III STR1VE13,14
studies provide some support for this hypothesis. Infants in START
with baseline CHOP INTEND scores greater than 20 who received

gene therapy before 3 months of age were the earliest to sit independently, and two patients who achieved independent walking were treated prior to age 3 months and had a baseline CHOP
INTEND score >40 18,22. Similarly, greater efficacy of other SMA
disease-modifying treatments has been observed when administered earlier in the course of the disease23,24. For example, presymptomatic infants treated with nusinersen in NURTURE achieved
greater clinical improvement compared with symptomatic patients,
as demonstrated by changes in Hammersmith Infant Neurological
Examination Section 2 (HINE-2) and CHOP INTEND scores23.
SPR1NT enrolled infants with a genetic diagnosis of SMA, two
or three copies of SMN2, and no clinical evidence of neuromuscular disease. The trial focused on clinically meaningful measures of
efficacy, such as motor milestones compared with normal developmental benchmarks25 and the ability to survive and thrive without
mechanical interventions, as they compared with a matched PNCR
natural-history cohort7. Here, we report final efficacy and safety
outcomes for children with two SMN2 copies (hereafter referred to
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Table 1 | Demographics and baseline clinical characteristics
(ITT population)
Baseline characteristics
Age at dosing, days

All patients (n = 14)

a

Mean (s.d.)

20.6 (7.9)

Median (range)

21.0 (8–34)

Gestational age at birth, weeks
Mean (s.d.)

38.2 (1.4)

Median (range)

38.0 (36–41)

Weight at baseline, kg
Mean (s.d.)

3.6 (0.39)

Median (range)

3.7 (3.0–4.3)

Sex, n (%)
Male

4 (29)

Female

10 (71)

Race, n (%)
White

7 (50)

Other

4 (29)

Asian

2 (14)

Black or African American

1 (7)

American Indian or Alaska Native

0

Native Hawaiian or other Pacific Islander

0

Ethnicity, n (%)
Not Hispanic or Latino

10 (71)

Hispanic or Latino

4 (29)

Modality of SMA diagnosis, n (%)
Prenatal testing

5 (36)

Newborn screening

9 (64)

c.859G>C SMN2 gene modifier variant

0

Age at SMA diagnosis, daysb
n (number of patients diagnosed after birth)

9

Mean (s.d.)

7.2 (4.8)

Median (range)

8.0 (1–14)

ITT, intention-to-treat; s.d., standard deviation; SMA, spinal muscular atrophy; SMN2, survival motor
neuron 2 gene. aAge at dosing = (dose date – date of birth + 1). bAge at SMA diagnosis = (SMA
diagnosis date ‒ date of birth + 1). Only calculated for patients who were diagnosed after birth.
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Fig. 1 | Survival and achieved video-confirmed developmental motor milestones. a, Milestones achieved (visit month identified). Months calculated
as days/30. Only the first observed instance of a milestone is included in this figure. aBayley Scales gross motor subtest item #26: child sits alone
without support for at least 30 seconds. bBayley Scales gross motor subtest item #40: child stands alone. Child stands alone for at least 3 seconds after
you release his or her hands. cBayley Scales gross motor subtest item #43: child walks alone. Child takes at least five steps independently, displaying
coordination and balance. According to the WHO-MGRS windows for normal development, the 99th percentile (that is, upper bound of normal
development) of sitting and walking without support was 279 days and 534 days, respectively. b, Kaplan–Meier plot for event-free survival in the SPR1NT
two-copy (blue line) and PNCR (red line) cohorts. n = 4 males and n = 10 females; mean (s.d.) age at dosing, 20.6 (7.9) days.

Screening and demographics. Forty-four newborns were screened
for the SPR1NT study, and 14 in total were excluded (Supplementary
Table 1). The most common reasons for exclusion were clinical signs of SMA at screening (n = 4), baseline peroneal nerve to
tibialis anterior compound muscle action potential (CMAP) less

than 2 mV (n = 4), and elevated anti-AAV9 titers (n = 2). Fourteen
presymptomatic infants with genetically confirmed SMA and two
SMN2 copies (71% female) were enrolled and treated with onasemnogene abeparvovec (Supplementary Fig. 1). The first patient was
enrolled on 2 April 2018, and the last patient completed the study
on 4 December 2020.
Children in the two-copy cohort were born between 36 and
41 (median 38) gestational weeks, with a median weight of 3.3 kg
(range, 2.72–4.35 kg) (Table 1). Eleven children were born prior to a
gestational age at birth of <40 weeks (less than full-term gestation),
and one patient had a gestational age of <37 weeks. All 14 children
had biallelic SMN1 deletions and two SMN2 copies (no c.859C>G
modifier variants), detected presymptomatically through either
prenatal screening (n = 5, 36%) or newborn screening (n = 9, 64%).
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as the two-copy cohort). Fifteen children with three copies of SMN2
(three-copy cohort) are the focus of a companion manuscript in this
journal26. SPR1NT provides important new safety data about SMN
gene therapy in neonates that, coupled with efficacy results from
both the two-copy and three-copy cohorts, has critical implications
for newborn-screening programs and the timing of therapeutic
intervention.

Results

Articles

Primary endpoint and other motor milestones. All 14 (100%,
97.5% confidence interval (CI): 77–100%) children in the ITT population achieved the primary endpoint of independent sitting for at
least 30 seconds at any visit up to 18 months of age (Fig. 1a), compared with none of 23 untreated patients with SMA type 1 in the
PNCR cohort (P < 0.0001). Children in the two-copy cohort first sat
independently at a median age of 265 days (range, 172–354 days),
and 11 of 14 (79%) achieved this motor milestone within the World
Health Organization (WHO) normal developmental time window
of ≤279 days of age. Of 12 children assessed for independent sitting
at the end of study, all 12 (100%) retained this motor milestone at
18 months of age. The remaining two patients could not be assessed.
All 14 (100%) children achieved motor milestones as defined
by both the Bayley-III Scales of Infant and Toddler Development
(BSID) and the WHO Multicentre Growth Reference Study
(WHO-MGRS) that were video-confirmed by an independent
observer (Supplementary Tables 2 and 3). According to the BSID
definition, 11 of 14 (79%) children stood alone (seven (50%) within
the normal developmental window of ≤514 days).
The WHO-MGRS and BSID use slightly different criteria to
describe independent walking. The WHO-MGRS defines independent walking as the ability to take five or more steps in an upright
position, back straight, with one leg moving forward while the other
supports most of the body weight, without contacting a person or
object. BSID criteria define independent walking as the ability
to take at least five steps independently, displaying coordination
and balance. Nine of 14 (64%) children walked independently by
BSID criteria at a median age of 526 days (range, 367–564 days),
and 5 (36%) did so within the normal developmental window of
≤534 days. Ten of 14 children (71%) walked alone, as defined by
WHO-MGRS criteria, at a median age of 493 days (range, 367–564
days), and six (43%) did so within the normal developmental window of ≤534 days. A comprehensive listing of motor milestone
achievement is provided in Supplementary Table 4. The highest Bayley and WHO-MGRS motor milestones achieved are in
Supplementary Table 5.
Secondary endpoints. All 14 (100%) children in the two-copy
cohort were alive and free of permanent ventilation at 14 months
of age (first secondary endpoint), compared with 6 of 23 (26%)
patients in the PNCR cohort (P < 0.0001) (Fig. 1b). Ventilator-free
survival remained at 100% at the end of study. No child required
mechanical respiratory support (for example, cough-assist, bilevel
positive airway pressure, or invasive ventilatory support) of any
kind throughout the duration of the trial.
Thirteen (93%) children maintained weight at or above the
3rd percentile without the need for non-oral/mechanical feeding support at all visits up to 18 months of age (second secondary
endpoint, P < 0.0001) (Fig. 2). All 14 children (100%) remained
free of non-oral or mechanical feeding support throughout the
trial. Thirteen of 14 (93%) children maintained weight within
an age-appropriate reference range (defined as greater than the
3rd percentile from WHO child growth standards25) at all study
visits, and 13 of 14 (93%) tolerated thin liquids, as demonstrated
through a formal swallowing test at month 18. The remaining child
in the two-copy cohort was not assessed for their ability to swallow
1384
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Weight (kg)

The nine children referred through newborn screening had a
confirmed molecular diagnosis at a median age of 8 days (range,
1–14 days). At baseline, CHOP INTEND scores were between 28
and 57 (median 49), median peroneal CMAP was 3.9 mV (range,
2.1, 6.1 mV), and all children could swallow and breathe normally.
All 14 infants enrolled in the two-copy cohort received the
entire onasemnogene abeparvovec infusion without interruption at
median age 21 days of life (range, 8–34 days). All completed the
study and were included in the intention-to-treat (ITT) population.
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Fig. 2 | Body weight over time. Children achieved the ability to maintain
weight at or greater than the 3rd percentile, without the need for non-oral
or mechanical feeding support at any visit up to 18 months of age for
female (a) and male (b) individuals, according to the WHO child growth
standards25. Gray shading represents WHO growth standards for the 3rd
through 97th percentiles. n = 4 males and n = 10 females; mean (s.d.) age
at dosing, 20.6 (7.9) days.

thin liquids. Ultimately, 12 (86%) children were thriving at the
18-month study visit; they could tolerate thin liquids by mouth and
maintained an age-appropriate weight without mechanical feeding
support (P < 0.0001; Supplementary Table 6).
Exploratory endpoints. In addition to documenting motor milestones, ventilator-free survival, and growth, SPR1NT included a
number of other exploratory endpoints of motor function. CHOP
INTEND scores (maximum score of 64) increased rapidly during
the initial 3 months after onasemnogene abeparvovec infusion.
Similar to the mean (s.d.) scores observed in normally developing
children (47.2 (10.0) and 56.7 (5.8) at 0 and 3 months, respectively)8, the mean (s.d.) CHOP INTEND score for children in the
two-copy cohort was 46.1 (8.8) at baseline, which increased by
3.9 (8.3) 1 month after treatment, 11.2 (8.8) at the 3 months of
age visit, and 14.8 (8.1) at the visit at 6 months of age (Fig. 3a).
CHOP INTEND scores reached a median of 60 (range, 51–64)
by the 6-month study visit. All 14 children (100%) achieved
Nature Medicine | VOL 28 | July 2022 | 1381–1389 | www.nature.com/naturemedicine
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Fig. 3 | Patient-level motor function as assessed by CHOP INTEND and Bayley gross and fine motor scores. a, The dashed straight line represents a CHOP
INTEND score of 40, which is a score that untreated patients with SMA type 1 rarely achieve in the natural history of the disease7. Shading represents
the CHOP INTEND values obtained from normal healthy control infants in the NeuroNEXT study with the mean values presented as a solid purple
line8. NeuroNext infants were 6 months of age or younger and born between 36–42 weeks gestation and were evaluated using the Test of Infant Motor
Performance Screening Items (TIMPSI) and CHOP INTEND (for children who scored <41 on TIMPSI)8. The dashed gray line represents the mean change
in CHOP INTEND score observed in the NeuroNEXT study of children with SMA type 1 who did not receive disease-modifying treatments8. Children who
achieved three consecutive CHOP INTEND scores ≥58 were not tested further. Bayley scales gross motor (b) and fine motor (c) subtests. The Bayley scales
gross and fine motor normal ranges (±2 s.d.) are presented in gray highlights. n = 4 males and n = 10 females; mean (s.d.) age at dosing, 20.6 (7.9) days.

Gains in motor function were paralleled by electrophysiologic
evidence of improved motor nerve integrity. For 14 children in
the two-copy cohort, median peroneal CMAP values increased by
0.60 mV (range, −1.3, 4.0 mV) from a median baseline of 3.9 mV
(range, 2.1, 6.1), reaching a maximum post-baseline median value
of 4.5 mV (range, 2.6, 6.8) (Supplementary Table 9).

a CHOP INTEND score greater than 40, a threshold never
achieved in untreated SMA type 1 patients older than 6 months
of age (P < 0.0001)7,8, whose CHOP INTEND scores instead
decreased by an average 10.7 points between 6 and 12 months
of age8. All children in the SPR1NT two-copy cohort ultimately
achieved a CHOP INTEND score of at least 58 by 18 months of
age (P < 0.0001) (Supplementary Table 7).
All 14 children (100%) demonstrated incremental gains on
BSID gross and fine motor scales throughout the study duration,
and all improved at least 15 points from baseline at any visit up to
18 months of age (Fig. 3b,c and Supplementary Table 8). However,
BSID gross motor scores varied for children at the 18-month study
visit, and five children were below the ranges (±s.d.) for normally
developing children. These BSID raw scores were converted into
scaled scores to allow comparison with the normative mean and
distribution of BSID scores for unaffected peers. BSID-scaled
scores have a normative mean of 10 and standard deviation (s.d.)
of three, such that scaled scores of 4–16 represent two s.d. from
the normative mean and capture the 3rd to 97th percentile range
for normally developing children of similar age27. At one or more
post-baseline visit(s), all 14 children in the two-copy cohort had
a scaled score ≥4.0 (within 2 s.d. of the reference mean) on both
the gross motor and fine motor BSID assessments measured at the
same visit. Nine (64%) children achieved a scaled gross and fine
motor score of ≥4.0 at 18 months.

Safety endpoints. To mitigate the inflammatory response to AAV9,
all 14 children commenced oral prednisolone therapy 1 day prior
to onasemnogene abeparvovec infusion and completed a median
of 60 (range, 49–100) days of therapy. One hundred and fifty-nine
treatment-emergent AEs (TEAEs) were observed for the two-copy
cohort during the study (Supplementary Tables 10 and 11). Each
child experienced at least one TEAE, and five (36%) had at least one
TEAE deemed to be serious. Ten of 14 (71%) had at least one TEAE
considered by the investigator to be related to study treatment, but
none were serious.
Five categories of AESIs were analyzed: hepatotoxicity, thrombocytopenia, cardiac toxicity, TMA, and sensory abnormalities
suggestive of dorsal root ganglionopathy (Table 2). Seven hepatotoxicity AESIs occurred in three of 14 (21%) children. All events
were mild or moderate, clinically asymptomatic, considered
related to treatment, and resolved. One (7%) child had serum aminotransferase enzyme concentrations exceeding three times the
ULN beginning on Day 352 (that is, CTCAE grade 2), and this was
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Table 2 | Treatment-emergent adverse events of special interest
(safety population)

Discussion

resolved with prednisolone dose modification (Supplementary
Table 12). Two children experienced a total of four cardiac AESIs,
all of which were mild or moderate elevations of creatine phosphokinase, creatine phosphokinase-MB, or troponin I that were
asymptomatic and resolved with (n = 1) or without (n = 3) a temporary increase in the prednisolone dose (Supplementary Table 13).
Serum cardiac troponin I was not consistently tested in all children
but was elevated on four occasions for two children (maximum
0.153 μg/L on Day 13). Left ventricular ejection and shortening
fractions were normal on echocardiogram, and no intracardiac
thrombi were observed. Three thrombocytopenia-related AESIs
occurred in three children (n = 1, thrombocytopenia, n = 1, vessel puncture site bruise, and n = 1, platelet count decreased), all of
which were mild and resolved without intervention (Supplementary
Table 14). The investigator considered two events (thrombocytopenia and platelet count decreased) as possibly related to treatment. Both events occurred on Day 8 and resolved on Days 13 and
15, respectively, with no further events reported. None of these
children had platelets <75,000 cells/µL per laboratory data, and
all platelet counts were within normal limits at the last assessment.
No TMA events were reported during the study. Three of 14 (21%)
children demonstrated areflexia (n = 2) and hyporeflexia (n = 1),
both AESIs that fell within the dorsal root ganglionopathy-related
criteria; however, all were mild and considered unrelated to treatment (Supplementary Table 15). Two resolved and one (areflexia)
was ongoing at the end of study.

Neonates genetically at risk for SMA type 1 who were treated in this
study before 6 weeks of age, prior to symptom onset, collectively
achieved developmental milestones to an extent never reported
for either untreated patients with SMA type 1 or those treated
with onasemnogene abeparvovec after the onset of neuromuscular
symptoms. Without treatment, children with SMA type 1 never sit
independently, and those with the milder SMA type 2 phenotype
never achieve the ability to stand or walk. Residual motor deficits
were apparent for patients treated at an older age (median, 3.5 and
4.1 months, respectively) in STR1VE-US (n = 22) and STR1VE-EU
(n = 32). Only 64% of patients in STR1VE-US and 44% of patients
in STR1VE-EU achieved the independent sitting endpoint, and did
so at later median ages of 12.6 (US) and 15.9 (EU) months13,14. Only
one patient from each cohort walked by age 18 months13,14. In contrast, children in the two-copy cohort of SPR1NT achieved remarkable gains in motor milestones: 100% sat, 71% stood, and 71%
walked independently, and most did so within the normal developmental window. Exceptional motor and functional outcomes were
also observed for children in the three-copy cohort of SPR1NT26.
For children in the two-copy SPR1NT cohort, motor gains and
somatic growth nearly paralleled normal development while swallowing and respiratory function remained intact. Importantly, no
child required any form of mechanical feeding or respiratory support at any time point during the trial. In comparison, 32% of symptomatic STR1VE-US patients required feeding support at some
point during the study, and 18% required ventilatory support by
18 months of age13. Taken together, these data support the conclusion
that earlier identification through systematic newborn-screening
efforts and administration of onasemnogene abeparvovec prior to
symptom onset results in improved developmental outcomes and
greater functional independence.
Table 3 presents SPR1NT in the context of three other clinical trials, including two Phase III studies of onasemnogene abeparvovec
for symptomatic infants with two copies of SMN2 (STR1VE-US13
and STR1VE-EU14) and the Phase II study of infants with two or
three copies of SMN2 treated with nusinersen prior to symptom
onset (NURTURE)23. Overall, Table 3 highlights the importance of
treatment timing (that is, prior to the onset of clinical symptoms)
as an important factor influencing outcome. However, direct comparisons are limited by differences in trial design, including primary endpoints (for example, percentage of patients who achieved
‘sits without support’ BSID item #26 milestone for the SPR1NT
two-copy cohort versus time to death or respiratory intervention
for NURTURE) and eligibility criteria (for example, ability to tolerate thin liquids, peroneal CMAP ≥2 mV, presymptomatic SMA
type 1 or type 2 in SPR1NT versus ulnar CMAP ≥1 mV, absence of
hypoxia, and no clinical signs or symptoms suggestive of SMA in
NURTURE). Achievement of motor milestones in SPR1NT is also
distinguished by its stringency, requiring video-confirmed assessment by an independent observer in both the two- and three-copy
cohorts26. Regardless of these caveats, children with either few or no
clinical signs of SMA who receive treatment appear to achieve more
advanced developmental milestones.
In contrast with the natural history of SMA type 1, motor
improvements in SPR1NT were evident within 3 months of treatment, when many children had CHOP INTEND scores similar to
those of healthy peers8. Beyond this time interval, CHOP INTEND
scores for all children in the two-copy cohort remained greater than
40, a threshold never achieved by untreated patients with SMA type
1 older than 6 months of age7,8. All children in the two-copy cohort
continued to make incremental gains on BSID gross and fine motor
scales throughout the trial. These gains are also demonstrated in
the three-copy cohort as reported in our companion manuscript26.
Because motor neurons are post-mitotic, there is reason to speculate that transgene expression will be maintained in the spinal
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Category of AESI preferred term

SPR1NT two-copy
cohort (n = 14b) (%)

Hepatotoxicity
Any TEAE

3 (21)

Aspartate aminotransferase increased

3 (21)

Alanine aminotransferase increased

1 (7)

Gamma-glutamyltransferase increased

1 (7)

Thrombocytopenia
Any TEAE

3 (21)

Thrombocytopenia

1 (7)

Vessel puncture site bruise

1 (7)

Platelet count decreased

1 (7)

Cardiac adverse events
Any TEAE

2 (14)

Blood creatine phosphokinase MB increased

1 (7)

Blood creatine phosphokinase increased

1 (7)

Troponin increased

1 (7)

Sensory abnormalities suggestive of ganglionopathy
Any TEAE

3 (21)

Areflexia

2 (14)

Hyporeflexia

1 (7)

Thrombotic microangiopathya
Any TEAE

2 (14)

Thrombocytopenia

1 (7)

Platelet count decreased

1 (7)

AESI, adverse event of special interest; TEAE, treatment-emergent adverse event. No TEAE
representing thrombotic microangiopathy was identified. aThrombocytopenia and platelet count
decreased are TEAEs that also fall under the thrombotic microangiopathy AESI category. bSafety
population, n = 4 males and n = 10 females; mean (s.d.) age at dosing, 20.6 (7.9) days.
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Table 3 | Summary of SPR1NT results and other SMA studies and cohortsa
Onasemnogene abeparvovec
Symptomatic patients

Nusinersen

Presymptomatic children

Presymptomatic children

PNCR

STR1VE-US

STR1VE-EU

SPR1NT
SPR1NT
NURTUREb
NURTUREb
two-copy cohort three-copy cohort two-copy cohort23 three-copy cohort23

Intention-to-treat
population, n

23

22

32

14

15

15

10

SMN2 copies

2

2

2

2

3

2

3

Median (range) age at
diagnosis, days

N/A

67 (56–126)

76 (26–156)

8 (1–14)

8 (2–26)

N/A

N/A

Median (range) age at
infusion, days

N/A

105 (15–177)

123 (54–180) 21 (8–34)

32 (9–43)

19 (8–41)

23 (3–42)

Baseline median (range)
CHOP INTEND

32.5 (31–33)d 33.5 (18–52) 28.0 (14–55) 48.5 (28–57)

N/A

45.0 (25–60)

53.5 (40–60)

Baseline median (range)
CMAP amplitude, mVe

0.3 (0.04–1.1) N/A

N/A

3.9 (2.1–6.1)

4.1 (2.7–7.0)

3.2 (1.1–9.7)

4.0(0.2–7.0)

Sitting independently by
18 months, n (%)f

0

14 (64)

14 (44)

14 (100)

N/A

N/A

N/A

Sitting independently by
24 months, n (%)f

0

N/A

N/A

N/A

14 (93)

15 (100)

10 (100)

Standing independently
by 18 months of age,
n (%)f

0

1 (5)

1 (3)

11 (79)

N/A

N/A

N/A

Standing independently
by 24 months of age,
n (%)f

0

N/A

N/A

N/A

15 (100)

9 (60)

10 (100)

Walking independently
by 18 months, n (%)f

0

1 (5)

1 (3)

9 (64)

N/A

N/A

N/A

Walking independently
by 24 months, n (%)f

0

N/A

N/A

N/A

14 (93)

9 (60)

10 (100)

20 (91)

31 (97)

14 (100)

15 (100)

15 (100)

10 (100)

7

Alive without permanent 6 (26)g
ventilation at 18 months,
n (%)f

13

c

14

N/A, not available. aThere are no published head-to-head studies of onasemnogene abeparvovec and nusinersen. Differences in trial design, including primary endpoints, how endpoints were measured,
and eligibility criteria, make direct comparison of results from these studies infeasible. The PNCR measured CHOP INTEND, NURTURE measured WHO and HINE-2 criteria, and STR1VE-US and STR1VE-EU
measured WHO criteria and CHOP INTEND. bNURTURE results represent interim analysis at data cut of 29 March 2019. At the time of this analysis, the median age of the infants was 34.8 months
(25.7–45.4)23. cMedian (range) is reported as the interquartile range. dValues indicate median (interquartile range) obtained for patients with symptom onset <3 months of age, a group that included seven
patients with two SMN2 copies and one patient with three SMN2 copies. eUlnar CMAP amplitude recorded from the abductor digiti minimi muscle at baseline for the PNCR study (n = 34 patients with SMA
type 1; n = 23, two SMN2 copies and n = 9, three SMN2 copies) and peroneal CMAP amplitude recorded from the tibialis anterior muscle for the SPR1NT and NURTURE studies. fMilestones were evaluated
over different observation periods between studies, and included 18 months for STR1VE-US, STR1VE-EU, and the SPR1NT two-copy cohort, 24 months for the SPR1NT three-copy cohort, and a median
follow-up time of 35 months for NURTURE. gSurvival without permanent ventilation at 14 months.

cord long-term. Accordingly, we are conducting follow-up studies to determine longitudinal motor outcomes for up to 15 years
in children who participated in SPR1NT. Indeed, data from
the ongoing START extension study demonstrated that newly
acquired motor skills were maintained for 4.6–5.6 years after vector infusion for patients, some of whom also received nusinersen28.
Furthermore, new motor milestones were achieved after completion of the 24-month START parent study. Neither of the patients
in the therapeutic-dose cohort who achieved new milestones in the
24-month START study received nusinersen at any point28.
In this study, BSID gross motor scores varied for children at
the 18-month study visit. These inter-individual differences in
therapeutic response might, in part, reflect the extent of antenatal
developmental neuropathologic changes that can result from SMN
protein deficiency during fetal life29–32. Nevertheless, timely administration of SMN gene replacement prevents the rapid clinical deterioration normally observed in untreated patients with SMA type
1, likely by preventing denervation of motor units within the first
3 postnatal months33. In support of this idea, we observed median
peroneal CMAP values of the two-copy cohort increase by 0.60 mV

(range, –1.3, 4.0 mV) from baseline to the end of study. This contrasts with the age-dependent reduction in CMAP values observed
in untreated patients with SMA type 133.
Administration of onasemnogene abeparvovec between 8 and
34 days of age demonstrated a favorable safety profile13,14. TEAEs
of transient elevations of liver enzymes were asymptomatic and
generally mild. Platelet counts decreased transiently in a few children, but never below 75,000 cells/µL. None of the cardiac TEAEs
reported were associated with clinical signs or symptoms of cardiac
dysfunction, depressed cardiac function on echocardiograms, or
rhythm disturbances on electrocardiograms. No cases of TMA and
no events of thrombosis were reported in this study. Three children
had potential TEAEs that were sensory abnormalities suggestive of
dorsal root ganglionopathy: two children had areflexia and one had
hyporeflexia, both of which are common features of SMA34. None
of these children exhibited other obvious evidence of dorsal root
ganglionopathy, such as painful paresthesias, sensory loss, or ataxia,
although these signs may be difficult to detect in young children35,36.
However, all potential dorsal-root-ganglionopathy-related TEAEs
were considered unrelated to treatment, and two of these events
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resolved. The ongoing areflexia observed in one child may be reflective of underlying disease, as weak or absent deep tendon stretch
reflexes are universally observed in untreated patients with SMA
type 1. The favorable benefit–risk profile observed in the SPR1NT
two-copy cohort is consistent with observations from patients with
symptomatic SMA type 1 treated with onasemnogene abeparvovec
in STR1VE-US13. However, no serious TEAEs related to treatment were observed in SPR1NT two-copy patients, whereas three
(elevated hepatic aminotransferases in two patients and hydrocephalus in one patient) were observed in STR1VE-US13. Because
the immune system is relatively tolerant to non-self antigens during the neonatal period37, it is possible that a less vigorous immune
response against the vector capsid may occur in newborns.
With the availability of treatments like onasemnogene abeparvovec, there is even more urgency to identify children early in life
by newborn screening and to thereby prevent death and disability
by treating them presymptomatically. All children in the two-copy
cohort of SPR1NT were diagnosed by either newborn screening
(n = 9) or prenatal testing (n = 5) before overt signs of neuromuscular disease appeared. Presymptomatic diagnosis, when coupled
with an effective therapy with acceptable risk, underscores the four
Wilson and Jungner criteria38 most relevant to newborn screening
that apply to, and are fulfilled by, SMA. These criteria are (1) an
established natural history marked by significant burden of suffering and detectable preclinical phase; (2) the target population is
clearly defined, including optimal timing of treatment; (3) a positive
screening result triggers a consensus plan of action that includes a
confirmatory testing algorithm, beneficial intervention with acceptable risk, and follow-up plan; and (4) the screening platform is
robust, reproducible, and affordable at a population scale39. Several
pilot SMA newborn-screening programs preceded SPR1NT and now
comprise more than 3,700,000 neonates screened during 6 years40–44.
These studies demonstrate that SMN1 deletions are reliably detected
from dried filter paper blood spots using high-throughput methods
with excellent performance for marginal incremental cost44–53. They
also demonstrate that some neonates, particularly those with two
SMN2 copies, develop signs of disease in the first few weeks of life54,
consistent with several screen failures in SPR1NT. This emphasizes
the urgency of timely diagnosis and treatment afforded by newborn
screening. In the longer term, newborn screening coupled with presymptomatic treatment holds promise to improve health-related
quality of life and reduce overall medical costs for infants otherwise
expected to develop SMA type 1 47. On the basis of these considerations, SMA was added to the Recommended Uniform Screening
Panel in 2018 55,56. As of June 2022, 46 states screen for SMA, capturing 97% of US newborns (www.curesma.org), and similar programs
are taking hold worldwide.
Limitations of SPR1NT include the relatively small number of
participants, the use of the PNCR external comparator group, and
the exclusion of children with baseline CMAP <2 mV.
In this study, we demonstrate that onasemnogene abeparvovec,
administered during the first 6 weeks post-partum to infants with
biallelic SMN1 mutations and two SMN2 copies, but no clinical signs
of SMA, alters the natural course of disease and results in better
motor outcomes, ventilator-free survival, and nutritional and respiratory independence as compared with untreated patients with SMA
type 1 or those treated after symptom onset. Early onasemnogene
abeparvovec administration also has a favorable benefit–risk profile
in presymptomatic newborns ≤6 weeks of age. To the extent these
benefits endure, neonatal SMN gene-replacement therapy driven
by systematic newborn screening efforts holds promise to ease the
global burden of suffering caused by SMA type 1.
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Methods

Study design. SPR1NT was an open-label, single-arm, Phase III study
conducted at 16 sites in six countries (Australia, Belgium, Canada, Japan, the
United Kingdom, and the United States). The study was conducted in accordance
with the Declaration of Helsinki, International Council for Harmonisation/
Good Clinical Practice guidelines, and applicable regulatory requirements
(for example, those relating to informed consent and the protection of human
patients in biomedical research). The study was approved by institutional
review boards (IRBs) at all participating institutions (Advarra Center for IRB
Intelligence, Nationwide Children’s Hospital; UCLA Medical Center IRB #3,
David Geffen School of Medicine at University of California Los Angeles;
Nemours Office of Human Subjects Protection, Nemours Children’s Clinic;
Columbia University Medical Center IRB, Columbia University Medical Center;
Advarra Center for IRB Intelligence, Massachusetts General Hospital; Children’s
Hospital of Eastern Ontario Research Ethics Board, Children’s Hospital of
Eastern Ontario; Sydney Children’s Hospitals Network Human Research Ethics
Committee, Sydney Children’s Hospital; University of Pennsylvania IRB,
Clinic for Special Children; Tokyo Women’s Medical University IRB, Tokyo
Women’s Medical University Hospital; The Dubowitz Neuromuscular Centre
IRB, University College London; The Neuromuscular Center of Liège, CHU &
University of Liège), and written informed consent was obtained from parents or
legal guardians of enrolled patients.
Patients. The study included presymptomatic children with SMA genetically
defined by biallelic deletions of SMN1 with either two or three copies of SMN2
who were expected to develop SMA types 1 or 2, respectively. These children were
enrolled in two separate cohorts according to SMN2 copy number. Children with
SMN1 point mutations or the SMN2 gene modifier variant (c.859G>C) could
enroll, but those with the SMN2 gene modifier variant would not be included
in the intention-to-treat (ITT) population. Efficacy and safety findings for the
children with two SMN2 copies are reported. The study planned to enroll at least
14 children with two copies of SMN2 who met the ITT criteria and were ≤6 weeks
of age at the time of gene-replacement therapy (Day 1). Full eligibility criteria are
described in the Supplementary Material.
The Coronavirus Disease 2019 (COVID-19) pandemic did not impact
retention. All children enrolled in SPR1NT completed the study, and none
withdrew from the study or were lost to follow-up because of the COVID-19
pandemic. However, some scheduled study visits and assessments were delayed or
canceled because of restrictions caused by the COVID-19 pandemic.
Procedures. All children were admitted into the hospital for pretreatment baseline
procedures 1 day prior to infusion. Onasemnogene abeparvovec (1.1 × 1014 vg/kg)
was administered as a single intravenous infusion (given over approximately
60 minutes) between 10 April 2018 and 3 July 2019. In-patient safety monitoring
was conducted for a minimum of 24 hours post-infusion. All children received
prophylactic prednisolone (initially 1 mg/kg/day, increased to 2 mg/kg/day
following a protocol amendment in May 2019) beginning 24 hours pre-infusion
and for 48 hours post-infusion, after which the dosage was 1 mg/kg/day through a
minimum of 30 days. Thereafter, prednisolone was tapered according to a standard
algorithm, and based on a requirement that gamma-glutamyl transferase, alanine
aminotransferase, and aspartate aminotransferase values were below the threshold
of twice the ULN. Investigators were permitted to use other glucocorticosteroids
in place of prednisolone, alter the daily dosage of prednisolone, and alter the taper
schedule according to their clinical judgments.
Outpatient follow-up period consisted of assessments on Days 7, 14, 21, 30,
44, 51 (in Japan only), 60, and 72 post-dose, and then assessments at 3 months of
age and continuing every 3 months thereafter through the 18 months of age (end
of study) visit. All eligible children were invited to enroll in an ongoing long-term
follow-up study (LT-002, NCT04042025).
Outcomes. The primary efficacy endpoint was the ability to sit independently
for ≥30 seconds at any visit up to 18 months of age, as stipulated by item #26
from the gross motor subtest of the BSID27. Secondary endpoints were survival
at 14 months of age, defined as the avoidance of death or requirement of
permanent ventilation (tracheostomy or ≥16 hours daily respiratory assistance
for ≥14 consecutive days in the absence of an acute reversible illness, excluding
perioperative ventilation) and the ability to maintain body weight at or greater
than the 3rd percentile at all visits without the need for feeding support at any
visit up to 18 months of age. Exploratory endpoints included achievement of
motor milestones as assessed by WHO-MGRS and BSID version 3 gross motor
criteria, CHOP INTEND scores, and scores on the BSID gross and fine motor
subtests27. Videos demonstrating developmental milestones meeting WHO
and BSID criteria (as part of clinical evaluation at study visits or submitted by
parent(s)/legal guardian(s) at any time during the study) were reviewed by an
independent, central reviewer for unbiased assessment and confirmation of
developmental milestone achievement. Patients who achieved three consecutive
CHOP INTEND scores ≥58 did not continue CHOP INTEND assessments.
Pulmonary examinations were performed by a pulmonologist or appropriate
individual as per standard institutional practice.
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Safety monitoring. Safety was assessed by monitoring for AE incidence and
severity, physical examinations, pulmonary examinations, vital sign assessments,
weight and length measurements, 12-lead electrocardiogram, 24-hour Holter
monitoring, echocardiograms, swallowing tests, laboratory assessments, and
photographs of the infusion site. TEAEs included any undesirable medical
condition occurring at any time, including baseline, even if no study treatment had
been administered.
All AEs were recorded and classified in accordance with the Common
Terminology Criteria for Adverse Events (version 4.03) (https://www.eortc.be/
services/doc/ctc/ctcae_4.03_2010-06-14_quickreference_5×7.pdf). Serious AEs
occurring during the study phase met at least one of the following criteria: resulted
in death; was immediately life-threatening; required an in-patient hospitalization
or prolongation of existing hospitalization; resulted in a persistent or significant
disability or incapacity; resulted in a congenital abnormality or birth defect; or
was an important medical event that may have jeopardized the patient or required
medical intervention to prevent one of the listed outcomes. The following AESIs
were also analyzed: hepatotoxicity, thrombocytopenia, cardiac AEs, TMA, and
sensory abnormalities suggestive of dorsal root ganglionopathy. AESIs were
identified using TEAE Standardized Medical Dictionary for Regulatory Activities
(MedDRA) queries and Customized MedDRA queries related to these categories
(see Supplementary Methods for additional information). The relationship of
AEs to onasemnogene abeparvovec (unrelated, possibly related, probably related,
or definitely related) was determined by the site investigator. If there was any
valid reason, even if undetermined, for suspecting a possible cause-and-effect
relationship between the investigational product and the occurrence of the AE,
then the AE was considered related.
Statistical analysis. Data were analyzed using SAS version 9.4 software
(SAS Institute). Primary and secondary efficacy analyses were performed
for patients with biallelic SMN1 deletions and two copies of SMN2 without
the SMN2 gene modifier variant (c.859G>C), which is associated with a less
severe clinical course57, who were included in the ITT population. Primary and
secondary outcomes were compared with a cohort of patients from the PNCR
natural-history data set (all patients with SMA type 1, two copies of SMN2,
age at SMA onset ≤6 months, and age at SMA diagnosis ≤2 years; the SMN2
modifier mutation (c.859G>C) was not assessed in the PNCR study cohort.)13.
As a substitute for comparison against a rate of zero, we assumed that no more
than 0.1% of untreated patients with SMA type 1 achieved independent sitting
without support for ≥30 seconds up to 18 months of age or achieved the ability
to maintain weight at or above the 3rd percentile without the need for non-oral/
mechanical feeding support up to 18 months of age, and 26% of patients survived
at 14 months according to age-matched natural-history data7. This study was
designed to have >90% power with α = 0.025 to detect a significant difference
in independent sitting using a one-sided exact binomial test based on a sample
size of ≥14 patients into the ITT population as well as assumptions based on
a matched PNCR data set7 and START study data18,19. Formal testing for the
primary and secondary efficacy endpoints was performed using a hierarchical
approach to protect against Type I error as follows. First, the primary endpoint
of independent sitting ≥30 seconds was assessed. If the analysis of the primary
endpoint was determined to be statistically significant (P < 0.025), then formal
testing of the first secondary endpoint, percentage of patients that survived and
did not require permanent ventilation, was conducted. If the analysis of this
secondary endpoint was determined to be statistically significant (P < 0.05), then
formal testing of the second secondary endpoint, maintenance of weight ≥3rd
WHO percentile without feeding support at any visit up to 18 months of age,
was conducted.
The safety population included all children who received onasemnogene
abeparvovec, including children with SMN1 point mutations and those with the
c.859G>C SMN2 gene modifier variant (no patients with the c.859G>C SMN2
gene modifier variant were enrolled). Safety was evaluated through reported AEs
as well as objective data variables, including vital signs, physical examinations,
and laboratory studies. These data are presented in a descriptive fashion. AEs were
coded using an industry standardized MedDRA coding dictionary (version 23.0),
and AESIs were classified through specific predefined MedDRA terms.
Reporting summary. Further information on research design is available
in the Nature Research Reporting Summary linked to this article.

Data availability

A redacted version of the SPR1NT study protocol and a redacted version of the
statistical analysis plan are available at ClinicalTrials.gov (NCT03505099). Novartis
is committed to sharing clinical trial data with external researchers and has been
doing so voluntarily since 2014. Novartis is committed to sharing, upon request
from qualified external researchers and subsequent approval by an independent
review panel based upon scientific merit, anonymized patient-level and study-level
clinical trial data, and redacted clinical study reports, for medicines and indications
approved in the United States and Europe after the respective study is accepted for
publication. All data provided are anonymized to respect the privacy of patients
who have participated in the trial, in line with applicable laws and regulations.
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Life sciences study design
All studies must disclose on these points even when the disclosure is negative.
Sample size

This study was designed to have >90% power with α = 0.025 to detect a significant difference in independent sitting using a one-sided exact
binomial test based on a sample size of ≥14 patients into the ITT population as well as assumptions based on a matched PNCR data set and
START study data. Formal testing for the primary and secondary efficacy endpoints was performed using a hierarchical approach to protect
against Type I error as follows. First, the primary endpoint of independent sitting ≥30 seconds was assessed. If the analysis of the primary
endpoint was determined to be statistically significant (P<0.025), then formal testing of the first secondary endpoint, percentage of patients
that survived and did not require permanent ventilation, was conducted. If the analysis of this secondary endpoint was determined to be
statistically significant (P<0.05), then formal testing of the second secondary endpoint, maintenance of weight ≥3rd WHO percentile without
feeding support at any visit up to 18 months of age, was conducted.

Data exclusions

No data were excluded from the analyses.

Replication

This was an open-label single-arm study that included efficacy and safety assessments for each patient. Assessments were repeated for each
patient at the relevant follow-up visit as per protocol, but were not replicated for each patient at each time point.

Randomization

This was an open-label single-arm study. Patients were not randomized to study groups.

Blinding

This study was an open-label design and no blinding was used.
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Infants eligible for enrollment in the two-copy cohort of SPR1NT must have been genetically diagnosed with presymptomatic
spinal muscular atrophy (SMA) with two copies of SMN2, ≤6 weeks (≤42 days) of age at the time of treatment, were able to
tolerate thin liquids as demonstrated through a formal bedside swallowing test, had a baseline peroneal nerve to tibialis
anterior compound muscle action potential (CMAP) value of ≥2 mV, were at a gestational age of 35 to 42 weeks, were up-todate on childhood vaccinations that include palivizumab prophylaxis (also known as Synagis®) to prevent respiratory syncytial
virus infections, able and willing to follow the Consensus Statement for Standard of Care in Spinal Muscular Atrophy and
parent(s)/legal guardian(s) willing and able to complete the informed consent process and comply with study procedures and
visit schedule. Genetic diagnoses had to be obtained from an acceptable newborn or prenatal screening test method.
Fourteen presymptomatic infants with genetically confirmed SMA and two SMN2 copies (71% female) were enrolled and
treated with onasemnogene abeparvovec. Children in the two-copy cohort were born between 36 and 41 (median 38)
gestational weeks, with a median weight of 3.3 kg (range, 2.72–4.35 kg). Eleven children were born prior to a gestational age
at birth of <40 weeks (less than full-term gestation), and one patient had a gestational age of <37 weeks. All 14 children had
biallelic SMN1 deletions and two SMN2 copies (no c.859C>G modifier variants) detected presymptomatically through either
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Recruitment

Infants eligible for enrollment in the two-copy cohort of SPR1NT must have been genetically diagnosed with presymptomatic
spinal muscular atrophy (SMA) with two copies of SMN2, ≤6 weeks (≤42 days) of age at the time of treatment, were able to
tolerate thin liquids as demonstrated through a formal bedside swallowing test, had a baseline peroneal nerve to tibialis
anterior compound muscle action potential (CMAP) value of ≥2 mV, were at a gestational age of 35 to 42 weeks, were up-todate on childhood vaccinations that include palivizumab prophylaxis (also known as Synagis®) to prevent respiratory syncytial
virus infections, able and willing to follow the Consensus Statement for Standard of Care in Spinal Muscular Atrophy and
parent(s)/legal guardian(s) willing and able to complete the informed consent process and comply with study procedures and
visit schedule. Genetic diagnoses had to be obtained from an acceptable newborn or prenatal screening test method.
SMA is a rare disease, and the study was conducted at specialized tertiary care centers. There were no active recruitment
efforts that would create bias.

Ethics oversight

The study was approved by institutional review boards at all participating institutions (Advarra Center for IRB Intelligence,
Nationwide Children’s Hospital; UCLA Medical Center IRB #3, David Geffen School of Medicine at University of California Los
Angeles; Nemours Office of Human Subjects Protection, Nemours Children’s Clinic; Columbia University Medical Center IRB,
Columbia University Medical Center; Advarra Center for IRB Intelligence, Massachusetts General Hospital; Children’s Hospital
of Eastern Ontario Research Ethics Board, Children’s Hospital of Eastern Ontario; Sydney Children’s Hospitals Network Human
Research Ethics Committee, Sydney Children’s Hospital; University of Pennsylvania IRB, Clinic for Special Children; Tokyo
Women’s Medical University IRB, Tokyo Women’s Medical University Hospital; The Dubowitz Neuromuscular Centre IRB,
University College London; The Neuromuscular Center of Liège, CHU & University of Liège), and written informed consent
was obtained from parents or legal guardians of enrolled patients.
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prenatal screening (n = 5, 36%) or newborn screening (n = 9, 64%). The nine children referred by newborn screening had a
confirmed molecular diagnosis at median age 8 days (range, 1–14 days).

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Clinical data
Policy information about clinical studies
All manuscripts should comply with the ICMJE guidelines for publication of clinical research and a completed CONSORT checklist must be included with all submissions.

Clinical trial registration ClinicalTrials.gov NCT03505099, registration date April 23, 2018.
Study protocol

A redacted version of the SPR1NT study protocol and a redacted version of the statistical analysis plan are available at
ClinicalTrials.gov.

Data collection

Data collection began between September 18, 2018, and July 9, 2019, at the time of onasemnogene abeparvovec infusion, and the
patients were followed for 18 months. Data collection was undertaken at 16 sites in six countries (Australia, Belgium, Canada, Japan,
United Kingdom, and the United States of America).

Outcomes

The primary efficacy endpoint was the ability to sit independently for ≥30 seconds at any visit up to 18 months of age, as stipulated
by item #26 from the gross motor subtest of the Bayley-III Scales of Infant and Toddler Development (BSID). Secondary endpoints
were survival at 14 months of age, defined as the avoidance of death or requirement of permanent ventilation (tracheostomy or ≥16
hours daily respiratory assistance for ≥14 consecutive days in the absence of an acute reversible illness, excluding perioperative
ventilation) and the ability to maintain body weight at or greater than the 3rd percentile at all visits without the need for feeding
support at any visit up to 18 months of age. Exploratory endpoints included achievement of motor milestones as assessed by WHO
Multicentre Growth Reference Study (WHO-MGRS) and BSID Version 3 Gross Motor criteria, Children’s Hospital of Philadelphia Infant
Test of Neuromuscular Disorders (CHOP INTEND) scores, and scores on the BSID gross and fine motor subtests. Videos demonstrating
developmental milestones meeting WHO and BSID criteria (as part of clinical evaluation at study visits or submitted by parent(s)/legal
guardian(s) at any time during the study) were reviewed by an independent, central reviewer for unbiased assessment and
confirmation of developmental milestone achievement. Patients who achieved three consecutive CHOP INTEND scores ≥58 did not
continue CHOP INTEND assessments.
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Primary and secondary efficacy analyses were performed for patients with biallelic SMN1 deletions and two copies of SMN2 without
the SMN2 gene modifier variant (c.859G>C), which is associated with a less severe clinical course, who were included in the ITT
population. Primary and secondary outcomes were compared with a cohort of patients from the PNCR natural history data set
described (all patients with SMA type 1, two copies of SMN2, age at SMA onset ≤6 months, and age at SMA diagnosis ≤2 years; the
SMN2 modifier mutation [c.859G>C] was not assessed in the PNCR study cohort.). As a substitute for comparison against a rate of
zero, we assumed that no more than 0.1% of untreated patients with SMA type 1 achieved independent sitting without support for
≥30 seconds up to 18 months of age or achieved the ability to maintain weight at or above the 3rd percentile without the need for
non-oral/mechanical feeding support up to 18 months of age, and 26% of patients survived at 14 months according to age-matched
natural history data. This study was designed to have >90% power with α = 0.025 to detect a significant difference in independent
sitting using a one-sided exact binomial test based on a sample size of ≥14 patients into the ITT population as well as assumptions
based on a matched PNCR data set and START study data. Formal testing for the primary and secondary efficacy endpoints was
performed using a hierarchical approach to protect against Type I error as follows. First, the primary endpoint of independent sitting
≥30 seconds was assessed. If the analysis of the primary endpoint was determined to be statistically significant (P<0.025), then
formal testing of the first secondary endpoint, percentage of patients that survived and did not require permanent ventilation, was
conducted. If the analysis of this secondary endpoint was determined to be statistically significant (P<0.05), then formal testing of the
second secondary endpoint, maintenance of weight ≥3rd WHO percentile without feeding support at any visit up to 18 months of
age, was conducted.
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